Pliant's Lead Drug Shows Promising Results in Chronic Liver Disease Study
Originally Published 2 years ago — by Endpoints News
Pliant Therapeutics has reported positive early-stage results from an exploratory study, indicating that patients with chronic liver disease who received its drug, bexotegrast, showed improved liver function compared to those who received a placebo. The study showed reduced levels of liver scarring biomarkers in patients who received the drug.